ORIGINAL ARTICLE

WILEY

Hypobaric live high-train low does not improve aerobic performance more than live low-train low in cross-country skiers

P. Robach^{1,2} | J. Hansen³ | A. Pichon⁴ | A.-K. Meinild Lundby⁵ | S. Dandanell^{6,7} |
G. Slettaløkken Falch³ | D. Hammarström³ | D. H. Pesta^{8,9} | C. Siebenmann⁵ |
S. Keiser¹⁰ | P. Kérivel¹ | J. E. Whist¹¹ | B. R. Rønnestad³ | C. Lundby⁵

Correspondence

Carsten Lundby, Center for Physical Activity Research, University Hospital of Copenhagen, Copenhagen, Denmark. Email: carsten.lundby@access.uzh.ch and

Paul Robach, Ecole Nationale des Sports de Montagne, site de l'Ecole Nationale de Ski et d'Alpinisme, Chamonix, France. Email: paul.robach@ensm.sports.gouv.fr

Funding information

Ministère des Sports/Institut National du Sport, de l'Expertise et de la Performance, Grant/Award Number: 15-R-03; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Grant/Award Number: 320030-143745; Zürich Center for Integrative Human Physiology; Municipality of Chamonix Live high-train low (LHTL) using hypobaric hypoxia was previously found to improve sea-level endurance performance in well-trained individuals; however, confirmatory controlled data in athletes are lacking. Here, we test the hypothesis that natural-altitude LHTL improves aerobic performance in cross-country skiers, in conjunction with expansion of total hemoglobin mass (Hb_{mass}, carbon monoxide rebreathing technique) promoted by accelerated erythropoiesis. Following duplicate baseline measurements at sea level over the course of 2 weeks, nineteen Norwegian cross-country skiers (three women, sixteen men, age 20 ± 2 year, maximal oxygen uptake (VO_2 max) 69 \pm 5 mL/min/kg) were assigned to 26 consecutive nights spent at either low (1035 m, control, n = 8) or moderate altitude (2207 m, daily exposure 16.7 ± 0.5 hours, LHTL, n = 11). All athletes trained together daily at a common location ranging from 550 to 1500 m (21.2% of training time at 550 m, 44.2% at 550-800 m, 16.6% at 800-1100 m, 18.0% at 1100-1500 m). Three test sessions at sea level were performed over the first 3 weeks after intervention. Despite the demonstration of nocturnal hypoxemia at moderate altitude (pulse oximetry), LHTL had no specific effect on serum erythropoietin, reticulocytes, Hb_{mass}, VO₂max, or 3000-m running performance. Also, LHTL had no specific effect on (a) running economy (VO2 assessed during steady-state submaximal exercise), (b) respiratory capacities or efficiency of the skeletal muscle (biopsy), and (c) diffusing capacity of the lung. This study, showing similar physiological responses and performance improvements in

¹Ecole Nationale des Sports de Montagne, site de l'Ecole Nationale de Ski et d'Alpinisme, Chamonix, France

²HP2, Université Grenoble Alpes, Grenoble, France

³Inland Norway University of Applied Sciences, Lillehammer, Norway

⁴Laboratory Mobility, Aging & Exercise (MOVE) - EA 6314, Faculty of Sport Sciences, University of Poitiers, Poitiers, France

⁵The Centre for Physical Activity Research, University Hospital of Copenhagen, Copenhagen, Denmark

⁶Center for Healthy Aging, Department of Biomedical Sciences, XLab, University of Copenhagen, Copenhagen, Denmark

⁷Department for Physiotherapy and Occupational Therapy, Metropolitan University College, Copenhagen, Denmark

⁸Department of Sport Science, Faculty for Sports Science and Psychology, University of Innsbruck, Innsbruck, Austria

⁹Department of Visceral, Transplant, and Thoracic Surgery, D. Swarovski Research Laboratory, Medical University of Innsbruck, Innsbruck, Austria

¹⁰Institute of Physiology, University of Zürich, Zürich, Switzerland

¹¹Innlandet Hospital Trust, Lillehammer, Norway